Arbutus Biopharma Future Growth
Future criteria checks 0/6
Arbutus Biopharma's revenue and earnings are forecast to decline at 12.9% and 18.6% per annum respectively while EPS is expected to decline by 15% per annum.
Key information
-18.6%
Earnings growth rate
-15.0%
EPS growth rate
Biotechs earnings growth | 20.7% |
Revenue growth rate | -12.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 01 Mar 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
May 21Arbutus Bio slips 4% as Q1 revenue trails consensus
May 05What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition
Mar 12We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Feb 02Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years
Jan 07Arbutus Biopharma (ABUS) Investor Presentation - Slideshow
Dec 17What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?
Dec 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 12 | -162 | N/A | N/A | 1 |
12/31/2025 | 10 | -96 | N/A | N/A | 3 |
12/31/2024 | 10 | -82 | N/A | N/A | 4 |
12/31/2023 | 18 | -73 | -87 | -86 | N/A |
9/30/2023 | 22 | -75 | -87 | -86 | N/A |
6/30/2023 | 24 | -73 | -84 | -83 | N/A |
3/31/2023 | 33 | -70 | -84 | -83 | N/A |
12/31/2022 | 39 | -69 | -36 | -35 | N/A |
9/30/2022 | 36 | -69 | -38 | -38 | N/A |
6/30/2022 | 33 | -76 | -36 | -35 | N/A |
3/31/2022 | 21 | -85 | -30 | -29 | N/A |
12/31/2021 | 11 | -88 | -68 | -68 | N/A |
9/30/2021 | 10 | -87 | -64 | -63 | N/A |
6/30/2021 | 8 | -84 | -60 | -59 | N/A |
3/31/2021 | 8 | -79 | -54 | -54 | N/A |
12/31/2020 | 7 | -76 | -52 | -51 | N/A |
9/30/2020 | 6 | -83 | -50 | -50 | N/A |
6/30/2020 | 8 | -147 | -61 | -61 | N/A |
3/31/2020 | 7 | -156 | -70 | -70 | N/A |
12/31/2019 | 6 | -165 | -72 | -71 | N/A |
9/30/2019 | 6 | -158 | -75 | -75 | N/A |
6/30/2019 | 5 | -100 | -65 | -64 | N/A |
3/31/2019 | 5 | -73 | -65 | -64 | N/A |
12/31/2018 | 6 | -67 | -69 | -68 | N/A |
9/30/2018 | 7 | -83 | -62 | -61 | N/A |
6/30/2018 | 12 | -68 | -65 | -64 | N/A |
3/31/2018 | 12 | -86 | -55 | -51 | N/A |
12/31/2017 | 11 | -85 | -56 | -49 | N/A |
9/30/2017 | 8 | -267 | N/A | -53 | N/A |
6/30/2017 | 2 | -275 | N/A | -52 | N/A |
3/31/2017 | 1 | -387 | N/A | -64 | N/A |
12/31/2016 | 1 | -384 | N/A | -58 | N/A |
9/30/2016 | 14 | -171 | N/A | -60 | N/A |
6/30/2016 | 18 | -180 | N/A | -47 | N/A |
3/31/2016 | 21 | -65 | N/A | -48 | N/A |
12/31/2015 | 23 | -63 | N/A | -56 | N/A |
9/30/2015 | 17 | -62 | N/A | -45 | N/A |
6/30/2015 | 17 | -42 | N/A | -49 | N/A |
3/31/2015 | 15 | -33 | N/A | -39 | N/A |
12/31/2014 | 15 | -39 | N/A | -12 | N/A |
9/30/2014 | 18 | -35 | N/A | -3 | N/A |
6/30/2014 | 17 | -33 | N/A | 0 | N/A |
3/31/2014 | 18 | -30 | N/A | 5 | N/A |
12/31/2013 | 15 | -14 | N/A | -7 | N/A |
9/30/2013 | 12 | 26 | N/A | 31 | N/A |
6/30/2013 | 12 | 29 | N/A | 33 | N/A |
3/31/2013 | 13 | 30 | N/A | 34 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABUS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABUS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABUS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABUS's revenue is expected to decline over the next 3 years (-12.9% per year).
High Growth Revenue: ABUS's revenue is forecast to decline over the next 3 years (-12.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ABUS's Return on Equity is forecast to be high in 3 years time